University of California

North Carolina State University

Stefano Menegatti

Samir M Mitragotri

Kathryn M Camacho

Sunny Kumar

Douglas Vogus

Ruben Guillermo Carbonell

Marta Broto

Benjamin G Bobay

Amith D Naik

Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.

Polymer-drug conjugates for combination anticancer therapy

Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.

Drug formulations for cancer treatment

Provided herein are novel hyaluronic acid-based materials for in-situ gelation in wounds and other contexts, which materials are biocompatible and which have favorable gelation kinetics. The resulting hydrogels have desirable rheological properties. The invention encompasses novel reagents for forming crosslinked hyaluronic acid hydrogels, with favorable kinetics for medical applications and having desirable and tunable physical properties. Also presented herein are methods of using the novel materials disclosed herein in wound care and other medical contexts.

Hyaluronic acid-based hydrogels having medical applications

This invention relates generally to the discovery of novel protease-resistant peptide ligands and uses thereof. Specifically, the present invention provides a protease-resistant peptide with three to twenty amino acids capable of binding a biological and comprising one or more basic amino acid(s) and I or aromatic amino acids, wherein one or more of the amino acids is substituted with a non-naturally occurring amino acid analog.

Protease-resistant peptide ligands

Compounds of Formulas I: and shorter variants thereof are described, along with solid supports having such compounds coupled thereto, and the use thereof as affinity ligands for antibodies.

Peptoid affinity ligands

This invention is directed to the production of improved chromatographic resins and method of making and using such resins.

Growing community of inventors

Raleigh, NC, United States of America

Stefano Menegatti